<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="pds" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">pds</book-part-id>
      <title-group>
        <title>Pyridoxine-Dependent Epilepsy</title>
        <alt-title alt-title-type="alt-title">Synonyms: Pyridoxine Dependency, Pyridoxine-Dependent Seizures, Vitamin B<sub>6</sub>-Dependent Seizures</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gospe</surname>
            <given-names>Sidney M</given-names>
            <suffix>Jr</suffix>
          </name>
          <degrees>MD, PhD</degrees>
          <aff>Herman and Faye Sarkowsky Endowed Chair of Child Neurology<break/>Professor, Neurology and Pediatrics<break/>University of Washington School of Medicine<break/>Seattle, Washington</aff>
          <email>sgospe@uw.edu</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>7</day>
          <month>12</month>
          <year>2001</year>
        </date>
        <date date-type="updated">
          <day>13</day>
          <month>4</month>
          <year>2017</year>
        </date>
        <date date-type="revised">
          <day>7</day>
          <month>6</month>
          <year>2012</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="pf" document-type="chapter">Pulmonary Fibrosis, Familial</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="pdc" document-type="chapter">Pyruvate Carboxylase Deficiency</related-object>
      <abstract id="pds.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Pyridoxine-dependent epilepsy is characterized by intractable seizures within the first weeks to months of life that are not controlled with antiepileptic drugs but respond both clinically and electrographically to large daily supplements of pyridoxine (vitamin B<sub>6</sub>). Multiple types of clinical seizures have been reported in individuals with pyridoxine-dependent epilepsy. Dramatic presentations consisting of prolonged seizures and recurrent episodes of status epilepticus are typical; recurrent self-limited events including partial seizures, generalized seizures, atonic seizures, myoclonic events, and infantile spasms also occur. Affected individuals may have electrographic seizures without clinical correlates. Infants with the classic neonatal presentation begin to experience seizures soon after birth. Atypical features include: late-onset seizures (seizures that begin from late infancy up until age 3 years); seizures that initially respond to antiepileptic drugs and then become intractable; seizures during early life that do not respond to pyridoxine but are then controlled with pyridoxine several months later; and prolonged seizure-free intervals (&#x02264;5.5 months) that occur after discontinuation of pyridoxine. Intellectual disability is common.</p>
          <p>Elevated concentration of &#x003b1;-aminoadipic semialdehyde (&#x003b1;-AASA) in urine and plasma is a strong biomarker of the disorder; pipecolic acid may also be elevated in plasma and cerebrospinal fluid.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of pyridoxine-dependent epilepsy is established in a proband: (a) showing a clinical response to pyridoxine administration followed by biochemical testing showing the presence of biomarkers; and/or (b) by the identification of biallelic pathogenic variants in <italic toggle="yes">ALDH7A1.</italic> Clinical diagnosis may be made in individuals experiencing status epilepticus or repetitive clinical seizures that are not controlled with antiepileptic drugs by concurrently administering 100 mg of pyridoxine intravenously while monitoring the EEG, oxygen saturation, and vital signs. In individuals with pyridoxine-dependent epilepsy, clinical seizures generally cease over several minutes. If a clinical response is not demonstrated, the dose should be repeated up to a maximum of 500 mg. A corresponding change should be observed in the EEG, although it may be delayed by several hours. Alternatively, in children who experience frequent antiepileptic drug-resistant self-limited seizures, oral pyridoxine at a dose of 30 mg/kg/day may be initiated. Children who are pyridoxine dependent should have a resolution of their clinical seizures within three to seven days.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Pyridoxine-dependent epilepsy is initially controlled with the addition of daily supplements of pyridoxine; subsequently, in the majority of affected individuals all antiepileptic drugs can be withdrawn and seizure control continued with daily pyridoxine monotherapy in pharmacologic doses. To prevent exacerbation of clinical seizures and/or encephalopathy during an acute illness, the daily dose of pyridoxine may be doubled for several days. Special education programs are offered to affected individuals.</p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> Overuse of pyridoxine can cause a reversible sensory neuropathy.</p>
          <p><italic toggle="yes">Surveillance</italic>: Monitoring for development of clinical signs of a sensory neuropathy and regular assessments of intellectual function.</p>
          <p>
            <italic toggle="yes">Evaluation of relatives at risk:</italic>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>If the pathogenic variants in the family are known, molecular genetic testing of at-risk newborn sibs of a proband for early diagnosis and treatment to reduce morbidity and mortality.</p>
            </list-item>
            <list-item>
              <p>If the pathogenic variants in the family are not known and the at-risk sib is experiencing clinical seizures or encephalopathy, administration of pyridoxine acutely (under EEG monitoring) for diagnostic and therapeutic purposes.</p>
            </list-item>
          </list>
          <p><italic toggle="yes">Pregnancy management</italic>: Supplemental maternal pyridoxine at a dose of 50-100 mg per day throughout the last half of pregnancy and after birth may be considered if the fetus is known to be affected or, if diagnostic prenatal testing is not pursued, in an at-risk fetus and neonate, until the diagnosis has been ruled out.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>Pyridoxine-dependent epilepsy is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk relatives and prenatal diagnosis for pregnancies at increased risk are possible if both pathogenic variants in a family are known.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="pds.Diagnosis">
        <title>Diagnosis</title>
        <sec id="pds.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p>Pyridoxine-dependent epilepsy <bold>should be suspected</bold> in individuals with the following clinical, family history, and supportive laboratory findings.</p>
          <p>
            <bold>Clinical features</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Seizures in any child under age one year without an apparent brain malformation as the cause of the epilepsy</p>
            </list-item>
            <list-item>
              <p>Cryptogenic seizures in a previously normal infant without an abnormal gestational or perinatal history</p>
            </list-item>
            <list-item>
              <p>Neonates with a phenotype suggestive of hypoxic ischemic encephalopathy and with difficult-to-control seizures</p>
            </list-item>
            <list-item>
              <p>The occurrence of long-lasting focal or unilateral seizures, often with partial preservation of consciousness</p>
            </list-item>
            <list-item>
              <p>Infants and children with seizures that are partially responsive to antiepileptic drugs, in particular if associated with developmental delay and intellectual disability</p>
            </list-item>
            <list-item>
              <p>Irritability, restlessness, crying, and vomiting preceding the actual seizures</p>
            </list-item>
            <list-item>
              <p>Individuals with a history of transient or unclear response of seizures to pyridoxine</p>
            </list-item>
            <list-item>
              <p>Infants and children with a history of seizures responsive to folinic acid</p>
            </list-item>
          </list>
          <p>
            <bold>Family history</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>A severe convulsive disorder in a sib, often leading to death during status epilepticus</p>
            </list-item>
            <list-item>
              <p>Parental consanguinity</p>
            </list-item>
          </list>
          <p>
            <bold>Supportive laboratory findings</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Elevated plasma and urinary alpha-aminoadipic semialdehyde (&#x003b1;-AASA)</p>
            </list-item>
            <list-item>
              <p>Elevated concentrations of <bold>pipecolic acid</bold> in plasma and cerebral spinal fluid</p>
              <p>Note: Pipecolic acid concentrations may normalize after many years of therapy [<xref ref-type="bibr" rid="pds.REF.plecko.2005.200">Plecko et al 2005</xref>].</p>
            </list-item>
            <list-item>
              <p>Analysis of cerebrospinal fluid <bold>monoamine metabolites</bold> via HPLC with electrochemical detection demonstrating:</p>
              <list list-type="bullet">
                <list-item>
                  <p>A pattern characteristic of pyridoxine-dependent epilepsy containing two peaks of unknown identity [<xref ref-type="bibr" rid="pds.REF.gallagher.2009.550">Gallagher et al 2009</xref>];</p>
                </list-item>
                <list-item>
                  <p>A characteristic chromatographic pattern of folinic acid-responsive seizures [<xref ref-type="bibr" rid="pds.REF.hyland.1995.177">Hyland et al 1995</xref>, <xref ref-type="bibr" rid="pds.REF.torres.1999.529">Torres et al 1999</xref>, <xref ref-type="bibr" rid="pds.REF.nicolai.2006.164">Nicolai et al 2006</xref>].</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p><bold>Newborn screening.</bold> The biomarker AASA has been shown to be present in blood specimens (newborn blood spots) from neonates subsequently diagnosed with pyridoxine-dependent epilepsy [<xref ref-type="bibr" rid="pds.REF.jung.2013.237">Jung et al 2013</xref>]. However, newborn screening for pyridoxine-dependent epilepsy is currently not available on a clinical basis.</p>
            </list-item>
          </list>
        </sec>
        <sec id="pds.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>The diagnosis of pyridoxine-dependent epilepsy <bold>is established</bold> in a proband showing a clinical response to pyridoxine administration, followed by biochemical testing showing the presence of biomarkers; and/or by the identification of biallelic pathogenic variants in <italic toggle="yes">ALDH7A1</italic> (see <xref ref-type="table" rid="pds.T.molecular_genetic_testing_used_in">Table 1</xref>).</p>
          <p><bold>A clinical diagnosis</bold> may be made:</p>
          <list list-type="bullet">
            <list-item>
              <p>On an acute basis in individuals experiencing clinical seizures by concurrently administering 100 mg of pyridoxine intravenously while monitoring the EEG, oxygen saturation, and vital signs [<xref ref-type="bibr" rid="pds.REF.baxter.2001.416">Baxter 2001</xref>, <xref ref-type="bibr" rid="pds.REF.stockler.2011.48">Stockler et al 2011</xref>]:</p>
              <list list-type="bullet">
                <list-item>
                  <p>In individuals with pyridoxine-dependent epilepsy, clinical seizures generally cease over a period of several minutes.</p>
                </list-item>
                <list-item>
                  <p>If a clinical response is not demonstrated, the dose should be repeated up to a maximum of 500 mg.</p>
                </list-item>
                <list-item>
                  <p>A corresponding change should be observed in the EEG; in some circumstances, the change may be delayed by several hours.</p>
                </list-item>
                <list-item>
                  <p>In some individuals with pyridoxine-dependent epilepsy, significant neurologic and cardiorespiratory depression follows this trial, making close systemic monitoring essential.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>By administering 30 mg/kg/day of pyridoxine orally. In individuals with pyridoxine-dependent epilepsy, clinical seizures should cease within three to five days [<xref ref-type="bibr" rid="pds.REF.baxter.2001.416">Baxter 2001</xref>, <xref ref-type="bibr" rid="pds.REF.gospe.2006.148">Gospe 2006</xref>, <xref ref-type="bibr" rid="pds.REF.stockler.2011.48">Stockler et al 2011</xref>].</p>
            </list-item>
          </list>
          <p>Note: In the past, the clinical diagnosis of pyridoxine-dependent epilepsy was confirmed by withdrawing antiepileptic drugs, followed by the withdrawal of daily pyridoxine supplementation and then successfully treating a recurrence of seizures with pyridoxine. Now that measurement of biomarkers supportive of a diagnosis of pyridoxine-dependent epilepsy is clinically available, this sequence of therapeutic changes is not necessary. In an individual with a clinical phenotype suggestive of pyridoxine-dependent epilepsy, daily pyridoxine supplementation should be continued while biomarker testing is pursued.</p>
          <p>Molecular genetic testing approaches can include <bold>single-gene testing</bold> and use of a <bold>multi-gene panel</bold>:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Single-gene testing.</bold> Sequence analysis of <italic toggle="yes">ALDH7A1</italic> is performed first and followed by gene-targeted deletion/duplication analysis if only one or no pathogenic variant is found.</p>
            </list-item>
            <list-item>
              <p><bold>A multi-gene panel</bold> that includes <italic toggle="yes">ALDH7A1</italic> and other genes of interest (see <xref ref-type="sec" rid="pds.Differential_Diagnosis">Differential Diagnosis</xref>) may also be considered. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and over time. (2) Some multi-gene panels may include genes not associated with the condition discussed in this <italic toggle="yes">GeneReview</italic>; thus, clinicians need to determine which multi-gene panel provides the best opportunity to identify the genetic cause of the condition at the most reasonable cost while limiting secondary findings. (3) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing based tests.</p>
              <p>For more information on multi-gene panels click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.MultiGene_Panels" object-type="sec">here</related-object>.</p>
            </list-item>
          </list>
          <table-wrap id="pds.T.molecular_genetic_testing_used_in" orientation="portrait" position="anchor">
            <label>Table 1. </label>
            <caption>
              <p>Molecular Genetic Testing Used in Pyridoxine-Dependent Epilepsy</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_pds.T.molecular_genetic_testing_used_in_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_pds.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                  <th id="hd_h_pds.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of Probands with Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by This Method</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_pds.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                    <italic toggle="yes">ALDH7A1</italic>
                  </td>
                  <td headers="hd_h_pds.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>3</sup></td>
                  <td headers="hd_h_pds.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">99/100&#x000a0;<sup>4</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_pds.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>5</sup></td>
                  <td headers="hd_h_pds.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">8 individuals with exon deletions&#x000a0;<sup>4</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_pds.T.molecular_genetic_testing_used_in_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Unknown&#x000a0;<sup>6</sup></td>
                  <td headers="hd_h_pds.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">NA</td>
                  <td headers="hd_h_pds.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="pds.TF.1.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="pds" object-id="pds.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
              </fn>
              <fn id="pds.TF.1.2">
                <label>2. </label>
                <p>See <xref ref-type="sec" rid="pds.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
              </fn>
              <fn id="pds.TF.1.3">
                <label>3. </label>
                <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="pds.TF.1.4">
                <label>4. </label>
                <p>99 /100 families with individuals with both clinical and biomarker evidence of pyridoxine dependent epilepsy had two identifiable pathogenic variants identified by sequence analysis or deletion analysis. Of these 99 kindreds, 91 affected individuals had two pathogenic variants identified by sequence analysis [<xref ref-type="bibr" rid="pds.REF.mills.2006.307">Mills et al 2006</xref>, <xref ref-type="bibr" rid="pds.REF.kanno.2007.384">Kanno et al 2007</xref>, <xref ref-type="bibr" rid="pds.REF.plecko.2007.19">Plecko et al 2007</xref>, <xref ref-type="bibr" rid="pds.REF.bennett.2009.1167">Bennett et al 2009</xref>, <xref ref-type="bibr" rid="pds.REF.mills.2010.2148">Mills et al 2010</xref>, <xref ref-type="bibr" rid="pds.REF.scharer.2010.571">Scharer et al 2010</xref>, <xref ref-type="bibr" rid="pds.REF.p_rez.2013.239">P&#x000e9;rez et al 2013</xref>]. Seven additional affected individuals had one pathogenic variant identified by sequence analysis with the second variant demonstrated by deletion/deletion analysis [<xref ref-type="bibr" rid="pds.REF.kanno.2007.384">Kanno et al 2007</xref>, <xref ref-type="bibr" rid="pds.REF.plecko.2007.19">Plecko et al 2007</xref>, <xref ref-type="bibr" rid="pds.REF.mefford.2015.756">Mefford et al 2015</xref>]. One affected individual had biallelic large deletions [<xref ref-type="bibr" rid="pds.REF.p_rez.2013.239">P&#x000e9;rez et al 2013</xref>]. The one final affected individual with confirmed pyridoxine-dependent epilepsy had one pathogenic variant identified by sequence analysis and no second variant identified by either sequence analysis or deletion/duplication analysis [<xref ref-type="bibr" rid="pds.REF.kluger.2008.276">Kluger et al 2008</xref>, <xref ref-type="bibr" rid="pds.REF.mefford.2015.756">Mefford et al 2015</xref>].</p>
              </fn>
              <fn id="pds.TF.1.5">
                <label>5. </label>
                <p>Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.</p>
              </fn>
              <fn id="pds.TF.1.6">
                <label>6. </label>
                <p>Evidence for locus heterogeneity: a. Assignment to the chromosome 5q31 pyridoxine-dependent epilepsy locus was excluded on the basis of haplotype analysis in one of the six North American pyridoxine-dependent epilepsy pedigrees. The affected children in the family had late-onset infantile spasms responsive to pyridoxine therapy [<xref ref-type="bibr" rid="pds.REF.bennett.2005.143">Bennett et al 2005</xref>]. A later study failed to detect <italic toggle="yes">ALDH7A1</italic> pathogenic variants in these children and in two additional children presenting with pyridoxine-responsive late-onset infantile spasms [<xref ref-type="bibr" rid="pds.REF.bennett.2009.1167">Bennett et al 2009</xref>].b. Very late-onset pyridoxine-dependent epilepsy presented in a female age eight years in whom linkage to the 5q31 locus was excluded by haplotype analysis [<xref ref-type="bibr" rid="pds.REF.kabakus.2008.703">Kabakus et al 2008</xref>].c. Individuals with neonatal-onset pyridoxine-dependent epilepsy resulting from biallelic pathogenic variants in <italic toggle="yes">PROSC</italic> have been described (see <xref ref-type="sec" rid="pds.Differential_Diagnosis">Differential Diagnosis</xref>) [<xref ref-type="bibr" rid="pds.REF.darin.2016.1325">Darin et al 2016</xref>].</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
      </sec>
      <sec id="pds.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="pds.Clinical_Description">
          <title>Clinical Description</title>
          <p>The one clinical feature characteristic of all individuals with pyridoxine-dependent epilepsy is intractable seizures that are not controlled with antiepileptic drugs but that respond both clinically and electrographically to large daily supplements of pyridoxine.</p>
          <sec id="pds.Classic_PyridoxineDependent_Epilepsy">
            <title>Classic Pyridoxine-Dependent Epilepsy</title>
            <p>Multiple types of clinical seizures have been reported in individuals with pyridoxine-dependent epilepsy. Although dramatic presentations consisting of prolonged seizures and recurrent episodes of status epilepticus are typical, recurrent self-limited events including partial, generalized, and atonic seizures; myoclonic events; and infantile spasms also occur. Affected individuals may have electrographic seizures without clinical correlates.</p>
            <p>Newborns with the classic neonatal presentation begin to experience seizures soon after birth.</p>
            <list list-type="bullet">
              <list-item>
                <p>In retrospect, many mothers recount unusual intrauterine movements that may have started in the late second trimester and that likely represent fetal seizures [<xref ref-type="bibr" rid="pds.REF.baxter.2001.416">Baxter 2001</xref>].</p>
              </list-item>
              <list-item>
                <p>Affected neonates frequently have periods of encephalopathy (irritability, crying, fluctuating tone, poor feeding) that precede the onset of clinical seizures. Low Apgar scores, abnormal cord blood gases, and other abnormalities of blood chemistries may also be observed. For this reason, it is not uncommon for these newborns to be diagnosed with hypoxic-ischemic encephalopathy [<xref ref-type="bibr" rid="pds.REF.baxter.1999.431">Baxter 1999</xref>, <xref ref-type="bibr" rid="pds.REF.mills.2010.2148">Mills et al 2010</xref>, <xref ref-type="bibr" rid="pds.REF.van_karnebeek.2016.6">van Karnebeek et al 2016</xref>].</p>
              </list-item>
              <list-item>
                <p>Clinical seizures may be associated with facial grimacing and abnormal eye movements [<xref ref-type="bibr" rid="pds.REF.schmitt.2010.e133">Schmitt et al 2010</xref>].</p>
              </list-item>
            </list>
            <p>Similar periods of encephalopathy may be seen in older infants with pyridoxine-dependent epilepsy, particularly prior to recurrence of clinical seizures, which occur in children treated with pyridoxine whose vitamin requirement may have increased because of growth or intercurrent infection, particularly gastroenteritis.</p>
            <p>Intellectual disability, particularly with expressive language, is common in individuals with pyridoxine-dependent epilepsy.</p>
            <list list-type="bullet">
              <list-item>
                <p>It has been suggested that an earlier onset of clinical seizures corresponds to a worse prognosis for cognitive function, and the length of the delay in diagnosis and initiation of effective pyridoxine treatment correlates with increased handicaps [<xref ref-type="bibr" rid="pds.REF.baxter.2001.416">Baxter 2001</xref>, <xref ref-type="bibr" rid="pds.REF.kluger.2008.276">Kluger et al 2008</xref>, <xref ref-type="bibr" rid="pds.REF.basura.2009.697">Basura et al 2009</xref>].</p>
              </list-item>
              <list-item>
                <p>Seizures in some individuals with molecularly confirmed pyridoxine-dependent epilepsy are incompletely controlled with pyridoxine, and concurrent treatment with one or more antiepileptic drugs is required. Significant intellectual disability is present in these individuals [<xref ref-type="bibr" rid="pds.REF.basura.2009.697">Basura et al 2009</xref>, <xref ref-type="bibr" rid="pds.REF.scharer.2010.571">Scharer et al 2010</xref>].</p>
              </list-item>
              <list-item>
                <p>Some affected individuals with normal intellectual function have been reported [<xref ref-type="bibr" rid="pds.REF.ohtsuka.1999.203">Ohtsuka et al 1999</xref>, <xref ref-type="bibr" rid="pds.REF.basura.2009.697">Basura et al 2009</xref>, <xref ref-type="bibr" rid="pds.REF.bok.2012.849">Bok et al 2012</xref>, <xref ref-type="bibr" rid="pds.REF.van_karnebeek.2016.6">van Karnebeek et al 2016</xref>].</p>
              </list-item>
              <list-item>
                <p>Few formal psychometric assessments in individuals with pyridoxine-dependent epilepsy have been performed. These limited studies have inconsistent findings. Two earlier studies indicate that verbal skills are more impaired than nonverbal skills [<xref ref-type="bibr" rid="pds.REF.baxter.1996.998">Baxter et al 1996</xref>, <xref ref-type="bibr" rid="pds.REF.baynes.2003.782">Baynes et al 2003</xref>] while a more recent report suggests that verbal IQ is slightly (but not significantly) higher than performance IQ [<xref ref-type="bibr" rid="pds.REF.bok.2012.849">Bok et al 2012</xref>].</p>
              </list-item>
            </list>
          </sec>
          <sec id="pds.Atypical_PyridoxineDependent_Epileps">
            <title>Atypical Pyridoxine-Dependent Epilepsy</title>
            <p>Late-onset and other atypical features of this phenotypically heterogeneous disorder have been described [<xref ref-type="bibr" rid="pds.REF.gouti_res.1985.117">Gouti&#x000e8;res &#x00026; Aicardi 1985</xref>, <xref ref-type="bibr" rid="pds.REF.coker.1992.221">Coker 1992</xref>, <xref ref-type="bibr" rid="pds.REF.basura.2009.697">Basura et al 2009</xref>, <xref ref-type="bibr" rid="pds.REF.van_karnebeek.2016.6">van Karnebeek et al 2016</xref>]. These include:</p>
            <list list-type="bullet">
              <list-item>
                <p>Late-onset seizures (seizures that begin during late infancy up until age 3 years)</p>
              </list-item>
              <list-item>
                <p>Seizures that initially respond to antiepileptic drugs and then become intractable</p>
              </list-item>
              <list-item>
                <p>Seizures during early life that do not respond to pyridoxine but that are then controlled with pyridoxine several months later</p>
              </list-item>
              <list-item>
                <p>Prolonged seizure-free intervals (age &#x02264;5.5 months) that occur after pyridoxine discontinuation</p>
              </list-item>
            </list>
          </sec>
          <sec id="pds.EEGNeuroimaging">
            <title>EEG/Neuroimaging</title>
            <p>While a variety of EEG abnormalities have been described in individuals with pyridoxine-dependent epilepsy, none is pathognomonic for this condition [<xref ref-type="bibr" rid="pds.REF.mikati.1991.215">Mikati et al 1991</xref>, <xref ref-type="bibr" rid="pds.REF.nabbout.1999.f125">Nabbout et al 1999</xref>, <xref ref-type="bibr" rid="pds.REF.naasan.2009.293">Naasan et al 2009</xref>, <xref ref-type="bibr" rid="pds.REF.bok.2010b.2406">Bok et al 2010b</xref>, <xref ref-type="bibr" rid="pds.REF.mills.2010.2148">Mills et al 2010</xref>, <xref ref-type="bibr" rid="pds.REF.schmitt.2010.e133">Schmitt et al 2010</xref>].</p>
            <p>Several imaging abnormalities have been reported in individuals with pyridoxine-dependent epilepsy:</p>
            <list list-type="bullet">
              <list-item>
                <p>Thinning of the corpus callosum (greatest in the isthmus and more rostral callosum) is universally seen [<xref ref-type="bibr" rid="pds.REF.friedman.2014.1106">Friedman et al 2014</xref>, <xref ref-type="bibr" rid="pds.REF.poliachik.2016.43">Poliachik et al 2016</xref>].</p>
              </list-item>
              <list-item>
                <p>Mega cisterna magma has been reported in a number of instances [<xref ref-type="bibr" rid="pds.REF.baxter.1996.998">Baxter et al 1996</xref>, <xref ref-type="bibr" rid="pds.REF.mills.2010.2148">Mills et al 2010</xref>, <xref ref-type="bibr" rid="pds.REF.friedman.2014.1106">Friedman et al 2014</xref>].</p>
              </list-item>
            </list>
          </sec>
        </sec>
        <sec id="pds.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>More than 80 <italic toggle="yes">ALDH7A1</italic> sequence alterations have been documented in both neonatal-onset and late-onset cases; however, no firm genotype-phenotype correlations are known [<xref ref-type="bibr" rid="pds.REF.mills.2006.307">Mills et al 2006</xref>, <xref ref-type="bibr" rid="pds.REF.kanno.2007.384">Kanno et al 2007</xref>, <xref ref-type="bibr" rid="pds.REF.plecko.2007.19">Plecko et al 2007</xref>, <xref ref-type="bibr" rid="pds.REF.rankin.2007.300">Rankin et al 2007</xref>, <xref ref-type="bibr" rid="pds.REF.salomons.2007.414">Salomons et al 2007</xref>, <xref ref-type="bibr" rid="pds.REF.bennett.2009.1167">Bennett et al 2009</xref>, <xref ref-type="bibr" rid="pds.REF.striano.2009.933">Striano et al 2009</xref>, <xref ref-type="bibr" rid="pds.REF.mills.2010.2148">Mills et al 2010</xref>, <xref ref-type="bibr" rid="pds.REF.scharer.2010.571">Scharer et al 2010</xref>, <xref ref-type="bibr" rid="pds.REF.stockler.2011.48">Stockler et al 2011</xref>, <xref ref-type="bibr" rid="pds.REF.bok.2012.849">Bok et al 2012</xref>, <xref ref-type="bibr" rid="pds.REF.p_rez.2013.239">P&#x000e9;rez et al 2013</xref>, <xref ref-type="bibr" rid="pds.REF.tlili.2013.242">Tlili et al 2013</xref>, <xref ref-type="bibr" rid="pds.REF.van_karnebeek.2015">van Karnebeek &#x00026; Gospe 2015</xref>, <xref ref-type="bibr" rid="pds.REF.mefford.2015.756">Mefford et al 2015</xref>, <xref ref-type="bibr" rid="pds.REF.van_karnebeek.2016.6">van Karnebeek et al 2016</xref>].</p>
          <p>The &#x0201c;common&#x0201d; p.Glu399Gln pathogenic variant in exon 14 (see <xref ref-type="sec" rid="pds.Molecular_Genetics">Molecular Genetics</xref>, <bold>Pathogenic variants</bold>) is responsible for approximately 30% of the mutated alleles. This pathogenic missense variant has been observed in both neonatal- and late-onset cases [<xref ref-type="bibr" rid="pds.REF.bennett.2009.1167">Bennett et al 2009</xref>].</p>
          <p>Pathogenic missense variants that result in residual enzyme activity may be associated with a more favorable developmental phenotype [<xref ref-type="bibr" rid="pds.REF.scharer.2010.571">Scharer et al 2010</xref>].</p>
        </sec>
        <sec id="pds.Prevalence">
          <title>Prevalence</title>
          <p>First described by <xref ref-type="bibr" rid="pds.REF.hunt.1954.140">Hunt et al [1954]</xref>, pyridoxine-dependent epilepsy is generally considered to be a rare cause of intractable neonatal seizures. Prior to the discovery of the biochemical and genetic abnormalities underlying pyridoxine-dependent epilepsy, approximately 100 affected individuals had been reported [<xref ref-type="bibr" rid="pds.REF.baxter.1999.431">Baxter 1999</xref>]. Subsequently, <italic toggle="yes">ALDH7A1</italic> sequence analysis has been conducted and reported on many of these individuals along with several others.</p>
          <p>A few epidemiologic studies of this condition have been conducted.</p>
          <list list-type="bullet">
            <list-item>
              <p>In the northern part of the United Kingdom, the prevalence of pyridoxine-dependent epilepsy in children younger than age 16 years was estimated at 1:100,000 [<xref ref-type="bibr" rid="pds.REF.baxter.1996.998">Baxter et al 1996</xref>].</p>
            </list-item>
            <list-item>
              <p>National studies in the United Kingdom and the Republic of Ireland noted a prevalence of approximately 1:700,000 [<xref ref-type="bibr" rid="pds.REF.baxter.1999.431">Baxter 1999</xref>].</p>
            </list-item>
            <list-item>
              <p>A survey conducted in the Netherlands estimated a birth incidence of 1:396,000 [<xref ref-type="bibr" rid="pds.REF.been.2005.1293">Been et al 2005</xref>].</p>
            </list-item>
            <list-item>
              <p>A study conducted in Germany, where pyridoxine administration is part of a standard treatment protocol for neonatal seizures, reported a birth incidence of probable cases of 1:20,000 [<xref ref-type="bibr" rid="pds.REF.ebinger.1999.795">Ebinger et al 1999</xref>].</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec id="pds.Genetically_Related_Allelic_Disorder">
        <title>Genetically Related (Allelic) Disorders</title>
        <p><bold>Folinic acid-responsive seizures</bold>. A small number of infants with intractable seizures either unresponsive or partially responsive to pyridoxine but responsive to folinic acid (folinic acid-responsive seizures) have been described [<xref ref-type="bibr" rid="pds.REF.hyland.1995.177">Hyland et al 1995</xref>, <xref ref-type="bibr" rid="pds.REF.torres.1999.529">Torres et al 1999</xref>, <xref ref-type="bibr" rid="pds.REF.nicolai.2006.164">Nicolai et al 2006</xref>]. Elevated levels of &#x003b1;-AASA and pathogenic variants in <italic toggle="yes">ALDH7A1</italic> have now been demonstrated in these children, indicating that folinic acid-responsive seizures are allelic to pyridoxine-dependent epilepsy [<xref ref-type="bibr" rid="pds.REF.gallagher.2009.550">Gallagher et al 2009</xref>].</p>
      </sec>
      <sec id="pds.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Pyridoxine-dependent epilepsy should be considered as a cause of intractable seizures presenting in neonates, infants, and children up to the third year of life for which an underlying lesion (i.e., symptomatic epilepsy) has not been identified. In particular, this diagnosis needs to be investigated in any neonate who presents with encephalopathy and seizures and in whom there is no convincing evidence of hypoxic-ischemic encephalopathy or other identifiable underlying metabolic disturbance [<xref ref-type="bibr" rid="pds.REF.baxter.1999.431">Baxter 1999</xref>, <xref ref-type="bibr" rid="pds.REF.stockler.2011.48">Stockler et al 2011</xref>].</p>
        <sec id="pds.Neonatal_and_Childhood_Epilepsy_Cond">
          <title>Neonatal and Childhood Epilepsy Conditions</title>
          <p>Other causes of intractable neonatal seizures include the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>"Folinic acid-responsive seizures" (see <xref ref-type="sec" rid="pds.Genetically_Related_Allelic_Disorder">Genetically Related Disorders</xref>)</p>
            </list-item>
            <list-item>
              <p>A variety of single gene disorders that result in neonatal/infantile seizures; the products of these genes may underlie the function of ion channels, signaling pathways, and transcription factors, among others [<xref ref-type="bibr" rid="pds.REF.mastrangelo.2012.24">Mastrangelo &#x00026; Leuzzi 2012</xref>]. In particular, affected individuals with pathogenic variants in <italic toggle="yes">KCNQ2</italic>, which encodes a neuronal potassium channel, may present with a neonatal epilepsy that does respond to treatment with pyridoxine [<xref ref-type="bibr" rid="pds.REF.mefford.2012.3190">Mefford et al 2012</xref>, <xref ref-type="bibr" rid="pds.REF.reid.2016.79">Reid et al 2016</xref>].</p>
            </list-item>
            <list-item>
              <p>Epileptic encephalopathies associated with copy number variants resulting in chromosome deletions or duplications [<xref ref-type="bibr" rid="pds.REF.mefford.2011.974">Mefford et al 2011</xref>]</p>
            </list-item>
            <list-item>
              <p>Lissencephaly or other brain malformations that are distinguishable by the presence of structural brain malformations (see <related-object link-type="booklink" source-id="gene" document-id="fcmd" document-type="chapter">Fukuyama Congenital Muscular Dystrophy</related-object>, <related-object link-type="booklink" source-id="gene" document-id="dcx" document-type="chapter"><italic toggle="yes">DCX</italic>-Related Disorders</related-object>, and <related-object link-type="booklink" source-id="gene" document-id="chrom17-lis" document-type="chapter"><italic toggle="yes">LIS1</italic>-Associated Lissencephaly/Subcortical Band Heterotopia</related-object>)</p>
            </list-item>
            <list-item>
              <p>Other rare inborn errors of metabolism that are identified by elevated ammonia, lactate, or anion gap on laboratory testing</p>
            </list-item>
            <list-item>
              <p>Severe acquired neurologic disorders such as intracerebral hemorrhage or infectious diseases (meningitis, encephalitis)</p>
            </list-item>
          </list>
          <p>Other causes of neonatal seizures in which elevated levels of &#x003b1;-AASA may be present:</p>
          <list list-type="bullet">
            <list-item>
              <p>Molybdenum cofactor deficiency (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/252150">252150</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/252160">252160</ext-link>, and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/615501">615501</ext-link>). This heterogeneous group of conditions can be distinguished from PDE by the presence of increased urinary xanthine, hypoxanthine, and S-sulfocysteine [<xref ref-type="bibr" rid="pds.REF.mills.2012.1031">Mills et al 2012</xref>, <xref ref-type="bibr" rid="pds.REF.struys.2012.e1716">Struys et al 2012</xref>]. Molybdenum cofactor deficiency is caused by biallelic pathogenic variants in <italic toggle="yes">MOCS1</italic>, <italic toggle="yes">MOCS2</italic>, or <italic toggle="yes">GPHN</italic>. Inheritance is autosomal recessive.</p>
            </list-item>
            <list-item>
              <p>Isolated sulfite oxidase deficiency (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/272300">272300</ext-link>). This condition can be distinguished from PDE by increased urinary sulfite and decreased urinary sulfate [<xref ref-type="bibr" rid="pds.REF.mills.2012.1031">Mills et al 2012</xref>]. It is caused by biallelic pathogenic variants in <italic toggle="yes">SUOX</italic>; inheritance is autosomal recessive.</p>
            </list-item>
          </list>
          <p><bold>Epilepsy, early-onset, vitamin B<sub>6</sub>-dependent</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/617290">617290</ext-link>) is caused by biallelic pathogenic variants in <italic toggle="yes">PROSC</italic> (<italic toggle="yes">pro</italic>lone <italic toggle="yes">s</italic>ynthetase <italic toggle="yes">c</italic>o-transcribed homolog [bacterial]), which encodes a protein that is involved in the intracellular homeostatic regulation of pyridoxal 5&#x02019;-phosphate (PLP), the biologically active form of pyridoxine [<xref ref-type="bibr" rid="pds.REF.darin.2016.1325">Darin et al 2016</xref>]. Seven individuals with this form of vitamin B<sub>6</sub>-dependent epilepsy have been reported (3 from 1 kindred) with six of the affected individuals experiencing clinical seizures on the first day of life while the first seizure in the other affected individual occurred at age one month. During intrauterine life, three of the affected individuals were reported to have abnormal intrauterine movements; four showed signs of fetal distress, including metabolic acidosis with increased blood lactate levels noted within the first few days of life. While all seven demonstrated a clinical response to pyridoxine treatment, five of the six surviving affected individuals also require the use of antiepileptic drugs. With the exception of the one person whose seizures developed at age one month, all affected individuals have acquired microcephaly. All of the six surviving affected individuals have some degree of speech, motor, and learning developmental delays.</p>
          <p><bold>Pyridoxine-responsive seizures.</bold> Some children with intractable seizures may have only partial improvement in seizure control with the addition of pyridoxine. In this situation, or in instances in which seizures recur after antiepileptic drugs are withdrawn and pyridoxine is continued, individuals who have not had molecular confirmation should not be diagnosed with pyridoxine-dependent epilepsy, but rather with "pyridoxine-responsive seizures" [<xref ref-type="bibr" rid="pds.REF.baxter.1999.431">Baxter 1999</xref>, <xref ref-type="bibr" rid="pds.REF.basura.2009.697">Basura et al 2009</xref>].</p>
          <p><bold>Inborn pyridoxine dependency states.</bold> While other inborn pyridoxine dependency states have been described (e.g., pyridoxine-dependent anemia and pyridoxine-dependent forms of <related-object link-type="booklink" source-id="gene" document-id="homocystinuria" document-type="chapter">homocystinuria</related-object>, xanthurenic aciduria [OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/236800">236800</ext-link>], and cystathioninuria [OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/219500">219500</ext-link>]), these conditions are not genetically related to pyridoxine-dependent epilepsy.</p>
          <p><bold>Pyridoxal phosphate-responsive epilepsy (<italic toggle="yes">PNPO</italic> associated)</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/610090">610090</ext-link>), a rare form of autosomal recessive neonatal epileptic encephalopathy, is caused by biallelic pathogenic variants in <italic toggle="yes">PNPO</italic> (<italic toggle="yes">PNPO</italic> encodes an enzyme that interconverts the phosphorylated forms of pyridoxine and pyridoxamine to the biologically active pyridoxal 5&#x02019;-phosphate [PLP]). The initial reports of PNPO deficiency described infants with pharmacoresistant epileptic encephalopathy in whom the seizures responded to PLP but not to pyridoxine, suggesting that this disorder is clinically distinct from pyridoxine-dependent epilepsy [<xref ref-type="bibr" rid="pds.REF.mills.2005.1077">Mills et al 2005</xref>, <xref ref-type="bibr" rid="pds.REF.hoffmann.2007.96">Hoffmann et al 2007</xref>, <xref ref-type="bibr" rid="pds.REF.bagci.2008.f151">Bagci et al 2008</xref>]. However, it was subsequently demonstrated that seizures in some individuals with PNPO deficiency actually responded to pyridoxine rather than to PLP [<xref ref-type="bibr" rid="pds.REF.pearl.2013.139">Pearl et al 2013</xref>, <xref ref-type="bibr" rid="pds.REF.mills.2014.1350">Mills et al 2014</xref>, <xref ref-type="bibr" rid="pds.REF.plecko.2014.1425">Plecko et al 2014</xref>]. Therefore, persons with an epileptic encephalopathy responsive to pyridoxine who do not have pathogenic variants in <italic toggle="yes">ALDH7A1</italic> or <italic toggle="yes">PROSC</italic> should have <italic toggle="yes">PNPO</italic> molecular genetic testing.</p>
          <p><bold>Other forms of pyridoxal phosphate-responsive epilepsy.</bold> Other children with intractable epilepsy who show a clinical response to pyridoxal phosphate rather than to pyridoxine have been reported [<xref ref-type="bibr" rid="pds.REF.wang.2005.512">Wang et al 2005</xref>]. The biochemical basis of the epileptic condition in these children has not been established [<xref ref-type="bibr" rid="pds.REF.baxter.2005.441">Baxter 2005</xref>, <xref ref-type="bibr" rid="pds.REF.gospe.2006.148">Gospe 2006</xref>].</p>
        </sec>
      </sec>
      <sec id="pds.Management">
        <title>Management</title>
        <sec id="pds.Evaluations_Following_Initial_Diagno">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with pyridoxine-dependent epilepsy, the following are appropriate:</p>
          <list list-type="bullet">
            <list-item>
              <p>Developmental assessment</p>
            </list-item>
            <list-item>
              <p>Consultation with a clinical geneticist and/or genetic counselor</p>
            </list-item>
          </list>
        </sec>
        <sec id="pds.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>In the majority of individuals with pyridoxine-dependent epilepsy, once seizures come under control with the addition of daily supplements of pyridoxine (see <xref ref-type="sec" rid="pds.Prevention_of_Primary_Manifestations">Prevention of Primary Manifestations</xref>), all antiepileptic drugs can be withdrawn, and seizure control will continue with daily pyridoxine monotherapy in pharmacologic doses.</p>
          <p>Special education programs should be offered.</p>
        </sec>
        <sec id="pds.Prevention_of_Primary_Manifestations">
          <title>Prevention of Primary Manifestations</title>
          <p>The effective treatment of individuals with pyridoxine-dependent epilepsy requires lifelong pharmacologic supplements of pyridoxine; the rarity of the disorder has precluded controlled studies to evaluate the optimal dose.</p>
          <p>The recommended daily allowance (RDA) for pyridoxine is 0.5 mg for infants and 2 mg for adults. In general, individuals with pyridoxine-dependent epilepsy have excellent seizure control when treated with 50-100 mg of pyridoxine per day. Seizures in some individuals are controlled on much smaller doses and others require somewhat higher doses [<xref ref-type="bibr" rid="pds.REF.basura.2009.697">Basura et al 2009</xref>, <xref ref-type="bibr" rid="pds.REF.stockler.2011.48">Stockler et al 2011</xref>].</p>
          <p>Affected individuals may have exacerbations of clinical seizures and/or encephalopathy during an acute illness, such as gastroenteritis or a febrile respiratory infection. To prevent such an exacerbation in these circumstances, the daily dose of pyridoxine may be doubled for several days until the acute illness resolves.</p>
          <p>Studies have indicated that higher doses may enhance intellectual development; it has been suggested that a dose of 15-30 mg/kg/day may be optimal [<xref ref-type="bibr" rid="pds.REF.baxter.2001.416">Baxter 2001</xref>, <xref ref-type="bibr" rid="pds.REF.stockler.2011.48">Stockler et al 2011</xref>] and that the dosage should not exceed 500 mg/day [<xref ref-type="bibr" rid="pds.REF.stockler.2011.48">Stockler et al 2011</xref>].</p>
          <p>Such therapy is required for life; affected individuals are metabolically dependent on the vitamin, rather than pyridoxine deficient. Compliance with pyridoxine supplementation is critical, as status epilepticus may develop within days of pyridoxine discontinuation.</p>
        </sec>
        <sec id="pds.Prevention_of_Secondary_Complication">
          <title>Prevention of Secondary Complications</title>
          <p>The overuse of pyridoxine must be avoided, as a reversible sensory neuropathy (ganglionopathy) caused by pyridoxine neurotoxicity can develop. While primarily reported in adults who have received "megavitamin therapy" with pyridoxine, sensory neuropathy has been reported in two persons with pyridoxine-dependent epilepsy [<xref ref-type="bibr" rid="pds.REF.mclachlan.1995.50">McLachlan &#x00026; Brown 1995</xref>, <xref ref-type="bibr" rid="pds.REF.rankin.2007.300">Rankin et al 2007</xref>], one of whom was an adolescent who developed a secondary cause of epilepsy and received a pyridoxine dose of 2 g/day [<xref ref-type="bibr" rid="pds.REF.mclachlan.1995.50">McLachlan &#x00026; Brown 1995</xref>].</p>
        </sec>
        <sec id="pds.Surveillance">
          <title>Surveillance</title>
          <p>Affected individuals should be followed for the development of clinical signs of a sensory neuropathy, including regular assessments of joint-position sense, ankle jerks, gait, and station [<xref ref-type="bibr" rid="pds.REF.baxter.2001.416">Baxter 2001</xref>, <xref ref-type="bibr" rid="pds.REF.stockler.2011.48">Stockler et al 2011</xref>].</p>
          <p>Regular assessments of intellectual function should be offered.</p>
        </sec>
        <sec id="pds.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Overuse of pyridoxine (see <bold>Prevention of Secondary Complications</bold>) is to be avoided.</p>
        </sec>
        <sec id="pds.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>Empiric treatment of the affected individual&#x02019;s newborn sib with pyridoxine supplementation should be offered until testing has been completed.</p>
          <p>If the <italic toggle="yes">ALDH7A1</italic> pathogenic variants in the family are known, molecular genetic testing is appropriate.</p>
          <p>If the pathogenic variants are not known, the following is recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>If a younger sib of a proband presents with encephalopathy or a seizure, pyridoxine should be administered acutely (ideally under EEG monitoring) for both diagnostic and therapeutic purposes.</p>
            </list-item>
            <list-item>
              <p>&#x003b1;-AASA is a sensitive biomarker for pyridoxine-dependent epilepsy while pipecolic acid is an indirect and less sensitive biomarker. If elevated plasma biomarker concentrations have been demonstrated in the proband, a similar elevation in a younger sib would support a diagnosis of pyridoxine-dependent epilepsy.</p>
            </list-item>
          </list>
          <p>Note: It would be unlikely for the proband's older sibs who have not experienced seizures to be pyridoxine dependent.</p>
          <p>See <xref ref-type="sec" rid="pds.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="pds.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>As recurrence risk for couples who have a child with this disorder is 25%, there is justification to treat the mother empirically with supplemental pyridoxine at a dose of 50-100 mg/day throughout the last half of her subsequent pregnancies and to treat the newborn with supplemental pyridoxine to prevent seizures and reduce the risk of neurodevelopmental disability [<xref ref-type="bibr" rid="pds.REF.baxter.1999.2082">Baxter &#x00026; Aicardi 1999</xref>, <xref ref-type="bibr" rid="pds.REF.bok.2010a.297">Bok et al 2010a</xref>]. It is important to emphasize, however, that at least one severe phenotype has been described in a family in which prenatal treatment of an at-risk sib did not result in an improved neurodevelopmental outcome [<xref ref-type="bibr" rid="pds.REF.rankin.2007.300">Rankin et al 2007</xref>].</p>
          <p>Molecular genetic testing of <italic toggle="yes">ALDH7A1</italic> can be performed prenatally or after birth; if both pathogenic variants are present, pyridoxine treatment should be continued during pregnancy (if prenatal testing is pursued and reveals the fetus to be affected) and after birth; if not, treatment can be withdrawn.</p>
        </sec>
        <sec id="pds.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>As <italic toggle="yes">ALDH7A1</italic> encodes the enzyme &#x003b1;-aminoadipic semialdehyde dehydrogenase (antiquitin), which is involved in cerebral lysine catabolism, it has been proposed that persons with pyridoxine-dependent epilepsy may benefit from a lysine-restricted diet. A small number of individuals have been treated in this fashion; improvements in development and behavior along with decreased biomarker levels have been described [<xref ref-type="bibr" rid="pds.REF.stockler.2011.48">Stockler et al 2011</xref>, <xref ref-type="bibr" rid="pds.REF.van_karnebeek.2012.335">van Karnebeek et al 2012</xref>]. A protocol for controlled therapeutic trials of lysine restriction in pyridoxine-dependent epilepsy has recently been proposed [<xref ref-type="bibr" rid="pds.REF.van_karnebeek.2014.1">van Karnebeek et al 2014</xref>].</p>
          <p>L-arginine competitively inhibits lysine transport and can therefore reduce lysine levels. Some individuals with pyridoxine-dependent epilepsy have difficulty tolerating a lysine-restricted medical diet; in such cases L-arginine supplementation has been offered as an alternative method of lowering lysine levels [<xref ref-type="bibr" rid="pds.REF.mercimekmahmutoglu.2014.741">Mercimek-Mahmutoglu et al 2014</xref>]. The effectiveness of treating pyridoxine-dependent epilepsy with &#x0201c;triple therapy&#x0201d; (a combination of pyridoxine supplementation, lysine restriction, and L-arginine supplementation) has also been studied [<xref ref-type="bibr" rid="pds.REF.coughlin.2015.35">Coughlin et al 2015</xref>, <xref ref-type="bibr" rid="pds.REF.mahajnah.2016.60">Mahajnah et al 2016</xref>], with promising results in a small number of treated individuals.</p>
          <p>A cellular proof of concept for antisense therapy of pyridoxine-dependent epilepsy has been reported [<xref ref-type="bibr" rid="pds.REF.p_rez.2013.239">P&#x000e9;rez et al 2013</xref>]. Specifically, the silent nucleotide change c.75C&#x0003e;T, a novel splicing variant creating a new donor splice site in exon 1, was rescued in a lymphoblast cell line via antisense therapy.</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
      </sec>
      <sec id="pds.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="pds.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Pyridoxine-dependent epilepsy is inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="pds.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected child are obligate heterozygotes (i.e., carriers of one <italic toggle="yes">ALDH7A1</italic> pathogenic variant).</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being a carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</p>
            </list-item>
            <list-item>
              <p>Even if the sibs of a proband are asymptomatic, molecular genetic testing to determine their genetic status should be considered for the purpose of early diagnosis and treatment of those who have inherited both pathogenic variants (see <xref ref-type="sec" rid="pds.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref>).</p>
            </list-item>
          </list>
          <p>
            <bold>Offspring of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Adults diagnosed with the disorder are being followed, but the fertility status of these individuals is not known, and there are no published reports concerning the offspring of individuals with pyridoxine-dependent epilepsy.</p>
            </list-item>
            <list-item>
              <p>Unless an individual with pyridoxine-dependent epilepsy has children with an affected individual or a carrier, his/her offspring will be obligate heterozygotes (carriers) for a pathogenic variant in <italic toggle="yes">ALDH7A1</italic>.</p>
            </list-item>
          </list>
          <p><bold>Other family members.</bold> Each sib of the proband's parents is at a 50% risk of being a carrier of an <italic toggle="yes">ALDH7A1</italic> pathogenic variant.</p>
        </sec>
        <sec id="pds.Carrier_Heterozygote_Detection">
          <title>Carrier (Heterozygote) Detection</title>
          <p>Carrier testing for at-risk relatives requires prior identification of the <italic toggle="yes">ALDH7A1</italic> pathogenic variants in the family.</p>
        </sec>
        <sec id="pds.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="pds.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="pds.Prenatal_Testing_and_Preimplantation">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once the <italic toggle="yes">ALDH7A1</italic> pathogenic variant has been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis for pyridoxine-dependent epilepsy are possible.</p>
        </sec>
      </sec>
      <sec id="pds.Resources">
        <title>Resources</title>
      </sec>
      <sec id="pds.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="pds.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis</title>
          <p>For many years, it was hypothesized that pyridoxine-dependent epilepsy was caused by an abnormality of the enzyme glutamic acid decarboxylase (GAD), which uses PLP as a cofactor. GAD converts glutamic acid, an excitatory neurotransmitter, into gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter. Both of these neurotransmitters play important roles in the control of epileptic processes. A number of clinical neurochemical studies indirectly supported this hypothesis. However, several laboratories failed to document genetic linkage of the phenotype to either isoform of GAD [<xref ref-type="bibr" rid="pds.REF.kure.1998.128">Kure et al 1998</xref>, <xref ref-type="bibr" rid="pds.REF.battaglioli.2000.309">Battaglioli et al 2000</xref>, <xref ref-type="bibr" rid="pds.REF.cormierdaire.2000.991">Cormier-Daire et al 2000</xref>].</p>
          <p>A genome-wide linkage scan of five families of North African descent (4 of whom were consanguineous) mapped a locus for pyridoxine-dependent epilepsy at chromosome 5q31 [<xref ref-type="bibr" rid="pds.REF.cormierdaire.2000.991">Cormier-Daire et al 2000</xref>]. <italic toggle="yes">ALDH7A1</italic> maps to this region. Pathogenic variants in <italic toggle="yes">ALDH7A1</italic> have been demonstrated to cause pyridoxine-dependent epilepsy. <italic toggle="yes">ALDH7A1</italic> encodes the protein &#x003b1;-aminoadipic semialdehyde dehydrogenase (also referred to as antiquitin), an aldehyde dehydrogenase with a previously unknown physiologic substrate [<xref ref-type="bibr" rid="pds.REF.lee.1994.371">Lee et al 1994</xref>]. It has now been demonstrated that antiquitin functions as a &#x00394;<sup>1</sup>-piperideine-6-carboxylate (P6C)-&#x003b1;-AASA dehydrogenase. Abnormal activity of this enzyme results in increased levels of P6C, which is the cyclic Schiff base of &#x003b1;-AASA; these two substances are in equilibrium with one another. P6C, in turn, inactivates PLP by condensing with the cofactor, likely resulting in abnormal metabolism of neurotransmitters [<xref ref-type="bibr" rid="pds.REF.mills.2006.307">Mills et al 2006</xref>]. Antiquitin has been shown to localize to radial glia, astrocytes, and ependymal cells but not to neurons. Deficiency of this protein in pyridoxine-dependent epilepsy is associated with neuronal migration abnormalities and other forms of brain dysgenesis, such as thinning of the corpus callosum [<xref ref-type="bibr" rid="pds.REF.friedman.2014.1106">Friedman et al 2014</xref>, <xref ref-type="bibr" rid="pds.REF.jansen.2014.22">Jansen et al 2014</xref>, <xref ref-type="bibr" rid="pds.REF.marguet.2016.1435">Marguet et al 2016</xref>, <xref ref-type="bibr" rid="pds.REF.poliachik.2016.43">Poliachik et al 2016</xref>]. These neurodevelopmental aspects of antiquitin deficiency are not reversible with pyridoxine treatment, lysine restriction, or L-arginine supplementation.</p>
          <p><bold>Gene structure.</bold>
<italic toggle="yes">ALDH7A1</italic> has 1809 bases and comprises 18 exons that range from 42 bp to 352 bp in size. The coding region is 1533 bp in length. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="pds" object-id="pds.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
          <p><bold>Pathogenic variants.</bold> Pathogenic variants have been documented in numerous affected families (see <xref ref-type="table" rid="pds.T.molecular_genetic_testing_used_in">Table 1</xref>). These include a variety of missense variants, single-base deletions, nonsense variants (probably leading to nonsense-mediated mRNA decay), splice site variants (predicted to cause exon skipping), and exon deletions. Individuals who are either homozygous for a particular pathogenic variant or compound heterozygous for two pathogenic variants have been reported [<xref ref-type="bibr" rid="pds.REF.mills.2006.307">Mills et al 2006</xref>, <xref ref-type="bibr" rid="pds.REF.kanno.2007.384">Kanno et al 2007</xref>, <xref ref-type="bibr" rid="pds.REF.plecko.2007.19">Plecko et al 2007</xref>, <xref ref-type="bibr" rid="pds.REF.rankin.2007.300">Rankin et al 2007</xref>, <xref ref-type="bibr" rid="pds.REF.salomons.2007.414">Salomons et al 2007</xref>, <xref ref-type="bibr" rid="pds.REF.kluger.2008.276">Kluger et al 2008</xref>, <xref ref-type="bibr" rid="pds.REF.bennett.2009.1167">Bennett et al 2009</xref>, Gallagher et all 2009, <xref ref-type="bibr" rid="pds.REF.striano.2009.933">Striano et al 2009</xref>, <xref ref-type="bibr" rid="pds.REF.mills.2010.2148">Mills et al 2010</xref>, <xref ref-type="bibr" rid="pds.REF.scharer.2010.571">Scharer et al 2010</xref>, <xref ref-type="bibr" rid="pds.REF.bok.2012.849">Bok et al 2012</xref>, <xref ref-type="bibr" rid="pds.REF.p_rez.2013.239">P&#x000e9;rez et al 2013</xref>, <xref ref-type="bibr" rid="pds.REF.tlili.2013.242">Tlili et al 2013</xref>, <xref ref-type="bibr" rid="pds.REF.mefford.2015.756">Mefford et al 2015</xref>].</p>
          <p>Nine pathogenic variants represent 61% of disease alleles and several studies have demonstrated that the glutamine 399 residue is mutated at a frequency of 33%, with the p.Glu399Gln (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/66348118">NM_001182.2</ext-link>:c.1195G&#x0003e;C) pathogenic variant being most common [<xref ref-type="bibr" rid="pds.REF.plecko.2007.19">Plecko et al 2007</xref>, <xref ref-type="bibr" rid="pds.REF.salomons.2007.414">Salomons et al 2007</xref>, <xref ref-type="bibr" rid="pds.REF.bennett.2009.1167">Bennett et al 2009</xref>, <xref ref-type="bibr" rid="pds.REF.mills.2010.2148">Mills et al 2010</xref>, <xref ref-type="bibr" rid="pds.REF.scharer.2010.571">Scharer et al 2010</xref>, <xref ref-type="bibr" rid="pds.REF.bok.2012.849">Bok et al 2012</xref>]. Exon 7 was involved in three of eight kindreds with pathogenic exon deletions in <italic toggle="yes">ALDH7A1</italic>, suggesting that exon 7 may be somewhat prone to deletion [<xref ref-type="bibr" rid="pds.REF.plecko.2007.19">Plecko et al 2007</xref>, <xref ref-type="bibr" rid="pds.REF.mefford.2015.756">Mefford et al 2015</xref>].</p>
          <p><bold>Normal gene product.</bold>
<italic toggle="yes">ALDH7A1</italic> encodes a protein with 510 amino-acid residues [<xref ref-type="bibr" rid="pds.REF.mills.2006.307">Mills et al 2006</xref>]. The deduced molecular weight of the encoded &#x00394;<sup>1</sup>-piperideine-6-carboxylate (P6C)-&#x003b1;-AASA dehydrogenase protein (antiquitin) is 55285 [<xref ref-type="bibr" rid="pds.REF.lee.1994.371">Lee et al 1994</xref>].</p>
          <p><bold>Abnormal gene product.</bold> In one study, the two missense variants, one nonsense variant, and the one documented single-base deletion all result in absent &#x003b1;-AASA dehydrogenase enzyme activity while the second nonsense variant resulted in &#x003b1;-AASA dehydrogenase enzyme activity that was 1.8% of normal [<xref ref-type="bibr" rid="pds.REF.mills.2006.307">Mills et al 2006</xref>]. The effect of selected <italic toggle="yes">ALDH7A1</italic> pathogenic variants on antiquitin function has been studied by expressing human antiquitin cDNA in <italic toggle="yes">E. coli</italic> with reduced or absent enzyme activity being demonstrated [<xref ref-type="bibr" rid="pds.REF.coultermackie.2012.478">Coulter-Mackie et al 2012</xref>, <xref ref-type="bibr" rid="pds.REF.coultermackie.2014.462">Coulter-Mackie et al 2014</xref>]. This experimental system may help characterize the pathogenicity of <italic toggle="yes">ALDH7A1</italic> variants. Molecular modeling indicates that missense variants are divided into three categories [<xref ref-type="bibr" rid="pds.REF.scharer.2010.571">Scharer et al 2010</xref>]:</p>
          <list list-type="bullet">
            <list-item>
              <p>Variants that affect NAD+ cofactor binding or catalysis;</p>
            </list-item>
            <list-item>
              <p>Variants that alter the substrate binding pocket; and</p>
            </list-item>
            <list-item>
              <p>Variants that potentially disrupt dimer or tetramer assembly of the antiquitin protein.</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec id="pds.References">
        <title>References</title>
        <sec id="pds.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="pds.Literature_Cited.reflist0">
            <ref id="pds.REF.bagci.2008.f151">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bagci</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zschocke</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoffmann</surname>
                    <given-names>GF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bast</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klepper</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muller</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heep</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bartmann</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Franz</surname>
                    <given-names>AR</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Pyridoxal phosphate-dependent neonatal epileptic encephalopathy.</article-title>
                <source>Arch Dis Child Fetal Neonatal Ed</source>
                <volume>93</volume>
                <fpage>F151</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">18296573</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.basura.2009.697">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Basura</surname>
                    <given-names>GJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagland</surname>
                    <given-names>SP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wiltse</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gospe</surname>
                    <given-names>SM</given-names>
                    <suffix>Jr</suffix>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Clinical features and the management of pyridoxine-dependent and pyridoxine-responsive seizures: review of 63 North American cases submitted to a patient registry.</article-title>
                <source>Eur J Pediatr</source>
                <volume>168</volume>
                <fpage>697</fpage>
                <lpage>704</lpage>
                <pub-id pub-id-type="pmid">18762976</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.battaglioli.2000.309">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Battaglioli</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosen</surname>
                    <given-names>DR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gospe</surname>
                    <given-names>SM</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Martin</surname>
                    <given-names>DL</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Glutamate decarboxylase is not genetically linked to pyridoxine-dependent seizures.</article-title>
                <source>Neurology</source>
                <volume>55</volume>
                <fpage>309</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">10908915</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.baxter.1999.431">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Baxter</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Epidemiology of pyridoxine dependent and pyridoxine responsive seizures in the UK.</article-title>
                <source>Arch Dis Child</source>
                <volume>81</volume>
                <fpage>431</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">10519720</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.baxter.2001.416">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Baxter</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Pyridoxine-dependent and pyridoxine-responsive seizures.</article-title>
                <source>Dev Med Child Neurol</source>
                <volume>43</volume>
                <fpage>416</fpage>
                <lpage>20</lpage>
                <pub-id pub-id-type="pmid">11409832</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.baxter.2005.441">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Baxter</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Pyridoxine or pyridoxal phosphate for intractable seizures?</article-title>
                <source>Arch Dis Child</source>
                <volume>90</volume>
                <fpage>441</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">15851419</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.baxter.1999.2082">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Baxter</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aicardi</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Neonatal seizures after pyridoxine use.</article-title>
                <source>Lancet</source>
                <volume>354</volume>
                <fpage>2082</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">10636399</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.baxter.1996.998">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Baxter</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Griffiths</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelly</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gardner-Medwin</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>1996</year>
                <article-title>Pyridoxine-dependent seizures: demographic, clinical, MRI and psychometric features, and effect of dose on intelligence quotient.</article-title>
                <source>Dev Med Child Neurol</source>
                <volume>38</volume>
                <fpage>998</fpage>
                <lpage>1006</lpage>
                <pub-id pub-id-type="pmid">8913181</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.baynes.2003.782">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Baynes</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Farias</surname>
                    <given-names>ST</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gospe</surname>
                    <given-names>SM</given-names>
                    <suffix>Jr</suffix>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Pyridoxine-dependent seizures and cognition in adulthood.</article-title>
                <source>Dev Med Child Neurol</source>
                <volume>45</volume>
                <fpage>782</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">14580135</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.been.2005.1293">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Been</surname>
                    <given-names>JV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bok</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andriessen</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Renier</surname>
                    <given-names>WO</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Epidemiology of pyridoxine dependent seizures in The Netherlands.</article-title>
                <source>Arch Dis Child</source>
                <volume>90</volume>
                <fpage>1293</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">16159904</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.bennett.2009.1167">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bennett</surname>
                    <given-names>CL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hahn</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Glass</surname>
                    <given-names>IA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gospe</surname>
                    <given-names>SM</given-names>
                    <suffix>Jr</suffix>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Prevalence of ALDH7A1 mutations in 18 North American pyridoxine-dependent seizure (PDS) patients.</article-title>
                <source>Epilepsia</source>
                <volume>50</volume>
                <fpage>1167</fpage>
                <lpage>75</lpage>
                <pub-id pub-id-type="pmid">19128417</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.bennett.2005.143">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bennett</surname>
                    <given-names>CL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huynh</surname>
                    <given-names>HM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chance</surname>
                    <given-names>PF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Glass</surname>
                    <given-names>IA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gospe</surname>
                    <given-names>SM</given-names>
                    <suffix>Jr</suffix>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Genetic heterogeneity for autosomal recessive pyridoxine-dependent seizures.</article-title>
                <source>Neurogenetics</source>
                <volume>6</volume>
                <fpage>143</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">16075246</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.bok.2010a.297">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bok</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Been</surname>
                    <given-names>JV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Struys</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rijper</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Willemsen</surname>
                    <given-names>MA</given-names>
                  </name>
                </person-group>
                <year>2010a</year>
                <article-title>Antenatal treatment in two Dutch families with pyridoxine-dependent seizures.</article-title>
                <source>Eur J Pediatr.</source>
                <volume>169</volume>
                <fpage>297</fpage>
                <lpage>303</lpage>
                <pub-id pub-id-type="pmid">19588165</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.bok.2012.849">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bok</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Halbertsma</surname>
                    <given-names>FJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Houterman</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wevers</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vreeswijk</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Struys</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Der Hoeven</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sival</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Willemsen</surname>
                    <given-names>MA</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Long-term outcome in pyridoxine dependent epilepsy.</article-title>
                <source>Dev Med Child Neurol.</source>
                <volume>54</volume>
                <fpage>849</fpage>
                <lpage>54</lpage>
                <pub-id pub-id-type="pmid">22804844</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.bok.2010b.2406">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bok</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maurits</surname>
                    <given-names>NM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Willemsen</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Teune</surname>
                    <given-names>LK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poll-The</surname>
                    <given-names>BT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Coo</surname>
                    <given-names>IF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toet</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagebeuk</surname>
                    <given-names>EE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brouwer</surname>
                    <given-names>OF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Hoeven</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sival</surname>
                    <given-names>DA</given-names>
                  </name>
                </person-group>
                <year>2010b</year>
                <article-title>The EEG response to pyridoxine-IV neither identifies nor excludes pyridoxine-dependent epilepsy.</article-title>
                <source>Epilepsia.</source>
                <volume>51</volume>
                <fpage>2406</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">20887371</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.coker.1992.221">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Coker</surname>
                    <given-names>SB</given-names>
                  </name>
                </person-group>
                <year>1992</year>
                <article-title>Postneonatal vitamin B6-dependent epilepsy.</article-title>
                <source>Pediatrics</source>
                <volume>90</volume>
                <fpage>221</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">1641285</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.cormierdaire.2000.991">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cormier-Daire</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dagoneau</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nabbout</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burglen</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Penet</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Soufflet</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desguerre</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Munnich</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dulac</surname>
                    <given-names>O</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>A gene for pyridoxine-dependent epilepsy maps to chromosome 5q31.</article-title>
                <source>Am J Hum Genet</source>
                <volume>67</volume>
                <fpage>991</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">10978228</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.coughlin.2015.35">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Coughlin</surname>
                    <given-names>CR</given-names>
                    <suffix>2nd</suffix>
                  </name>
                  <name name-style="western">
                    <surname>van Karnebeek</surname>
                    <given-names>CD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al-Hertani</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shuen</surname>
                    <given-names>AY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jaggumantri</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jack</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gaughan</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burns</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mirsky</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gallagher</surname>
                    <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Hove</surname>
                    <given-names>JL</given-names>
                  </name>
                </person-group>
                <year>2015</year>
                <article-title>Triple therapy with pyridoxine, arginine supplementation and dietary lysine restriction in pyridoxine-dependent epilepsy: neurodevelopmental outcome.</article-title>
                <source>Mol Genet Metab.</source>
                <volume>116</volume>
                <fpage>35</fpage>
                <lpage>43</lpage>
                <pub-id pub-id-type="pmid">26026794</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.coultermackie.2012.478">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Coulter-Mackie</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lian</surname>
                    <given-names>Q</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Struys</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>St&#x000f6;ckler</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waters</surname>
                    <given-names>PJ</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Overexpression of human antiquitin in E. coli: enzymatic characterization of twelve ALDH7A1 missense mutations associated with pyridoxine-dependent epilepsy.</article-title>
                <source>Mol Genet Metab.</source>
                <volume>106</volume>
                <fpage>478</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">22784480</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.coultermackie.2014.462">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Coulter-Mackie</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tiebout</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Karnebeek</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stockler</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2014</year>
                <article-title>Overexpression of recombinant human antiquitin in E. coli: partial enzyme activity in selected ALDH7A1 missense mutations associated with pyridoxine-dependent epilepsy.</article-title>
                <source>Mol Genet Metab</source>
                <volume>111</volume>
                <fpage>462</fpage>
                <lpage>466</lpage>
                <pub-id pub-id-type="pmid">24613284</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.darin.2016.1325">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Darin</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reid</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prunetti</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Samuelsson</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Husain</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilson</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>El Yacoubi</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Footitt</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chong</surname>
                    <given-names>WK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilson</surname>
                    <given-names>LC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prunty</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pope</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heales</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lascelles</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Champion</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wassmer</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Veggiotti</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Cr&#x000e9;cy-Lagard</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mills</surname>
                    <given-names>PB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clayton</surname>
                    <given-names>PT</given-names>
                  </name>
                </person-group>
                <year>2016</year>
                <article-title>Mutations in PROSC disrupt cellular pyridoxal phosphate homeostasis and cause vitamin-B6-dependent epilepsy.</article-title>
                <source>Am J Hum Genet.</source>
                <volume>99</volume>
                <fpage>1325</fpage>
                <lpage>37</lpage>
                <pub-id pub-id-type="pmid">27912044</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.ebinger.1999.795">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ebinger</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schutze</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Konig</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Demographics and diagnosis of pyridoxine-dependent seizures.</article-title>
                <source>J Pediatr</source>
                <volume>134</volume>
                <fpage>795</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">10356240</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.friedman.2014.1106">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Friedman</surname>
                    <given-names>SD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ishak</surname>
                    <given-names>GE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poliachik</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poliakov</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Otto</surname>
                    <given-names>RK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shaw</surname>
                    <given-names>DWW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Willemsen</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bok</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gospe</surname>
                    <given-names>SM</given-names>
                  </name>
                </person-group>
                <year>2014</year>
                <article-title>Callosal alterations in pyridoxine-dependent epilepsy.</article-title>
                <source>Dev Med Child Neurol</source>
                <volume>56</volume>
                <fpage>1106</fpage>
                <lpage>10</lpage>
                <pub-id pub-id-type="pmid">24942048</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.gallagher.2009.550">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gallagher</surname>
                    <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Hove</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scharer</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hyland</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plecko</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waters</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mercimek-Mahmutoglu</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stockler-Ipsiroglu</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenberg</surname>
                    <given-names>EH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Struys</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Folinic acid-responsive seizures are identical to pyridoxine-dependent epilepsy.</article-title>
                <source>Ann Neurol</source>
                <volume>65</volume>
                <fpage>550</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">19142996</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.gospe.2006.148">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gospe</surname>
                    <given-names>SM</given-names>
                    <suffix>Jr</suffix>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Pyridoxine-dependent seizures: new genetic and biochemical clues to help with diagnosis and treatment.</article-title>
                <source>Curr Opin Neurol</source>
                <volume>19</volume>
                <fpage>148</fpage>
                <lpage>53</lpage>
                <pub-id pub-id-type="pmid">16538088</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.gouti_res.1985.117">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gouti&#x000e8;res</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aicardi</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>1985</year>
                <article-title>Atypical presentations of pyridoxine-dependent seizures: a treatable cause of intractable epilepsy in infants.</article-title>
                <source>Ann Neurol</source>
                <volume>17</volume>
                <fpage>117</fpage>
                <lpage>20</lpage>
                <pub-id pub-id-type="pmid">3977296</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.hoffmann.2007.96">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hoffmann</surname>
                    <given-names>GF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schmitt</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Windfuhr</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wagner</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strehl</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bagci</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Franz</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mills</surname>
                    <given-names>PB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clayton</surname>
                    <given-names>PT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baumgartner</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steinmann</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bast</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wolf</surname>
                    <given-names>NI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zschocke</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Pyridoxal 5'-phosphate may be curative in early-onset epileptic encephalopathy.</article-title>
                <source>J Inherit Metab Dis</source>
                <volume>30</volume>
                <fpage>96</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">17216302</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.hunt.1954.140">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hunt</surname>
                    <given-names>AD</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Stokes</surname>
                    <given-names>J</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>McCrory</surname>
                    <given-names>WW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stroud</surname>
                    <given-names>HH</given-names>
                  </name>
                </person-group>
                <year>1954</year>
                <article-title>Pyridoxine dependency: report of a case of intractable convulsions in an infant controlled by pyridoxine.</article-title>
                <source>Pediatrics</source>
                <volume>13</volume>
                <fpage>140</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">13133562</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.hyland.1995.177">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hyland</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buist</surname>
                    <given-names>NR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Powell</surname>
                    <given-names>BR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoffman</surname>
                    <given-names>GF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rating</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McGrath</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Acworth</surname>
                    <given-names>IN</given-names>
                  </name>
                </person-group>
                <year>1995</year>
                <article-title>Folinic acid responsive seizures: a new syndrome?</article-title>
                <source>J Inherit Metab Dis</source>
                <volume>18</volume>
                <fpage>177</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">7564240</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.jansen.2014.22">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jansen</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hevner</surname>
                    <given-names>RF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roden</surname>
                    <given-names>WH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hahn</surname>
                    <given-names>SH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jung</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gospe</surname>
                    <given-names>SM</given-names>
                    <suffix>Jr</suffix>
                  </name>
                </person-group>
                <year>2014</year>
                <article-title>Glial localization of antiquitin: Implications for pyridoxine-dependent epilepsy.</article-title>
                <source>Ann Neurol.</source>
                <volume>75</volume>
                <fpage>22</fpage>
                <lpage>32</lpage>
                <pub-id pub-id-type="pmid">24122892</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.jung.2013.237">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jung</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tran</surname>
                    <given-names>NT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gospe</surname>
                    <given-names>SM</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Hahn</surname>
                    <given-names>SH</given-names>
                  </name>
                </person-group>
                <year>2013</year>
                <article-title>Preliminary investigation of the use of newborn dried blood spots for screening pyridoxine-dependent epilepsy by LC-MS/MS.</article-title>
                <source>Mol Genet Metab.</source>
                <volume>110</volume>
                <fpage>237</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">23953072</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.kabakus.2008.703">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kabakus</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aydin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ugur</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Durukan</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tolun</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Very-late-onset pyridoxine-dependent seizures not linking to the known 5q31 locus.</article-title>
                <source>Pediatr Int</source>
                <volume>50</volume>
                <fpage>703</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">19261126</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.kanno.2007.384">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kanno</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kure</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Narisawa</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kamada</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takayanagi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamamoto</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoshino</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goto</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takahashi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haginoya</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tuschiya</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baumeister</surname>
                    <given-names>FAM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hasegawa</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aoki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamaguchi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsubara</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Allelic and non-allelic heterogeneities in pyridoxine dependent seizures revealed by ALDH7A1 mutational analysis.</article-title>
                <source>Mol Genet Metab</source>
                <volume>91</volume>
                <fpage>384</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">17433748</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.kluger.2008.276">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kluger</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blank</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paul</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paschke</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jansen</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>W&#x000f6;rle</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plecko</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Pyridoxine-dependent epilepsy: normal outcome in a patient with late diagnosis after prolonged status epilepticus causing cortical blindness.</article-title>
                <source>Neuropediatrics</source>
                <volume>39</volume>
                <fpage>276</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">19294602</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.kure.1998.128">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kure</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sakata</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyabayashi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takahashi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shinka</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsubara</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoshino</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Narisawa</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Mutation and polymorphic marker analyses of 65K- and 67K-glutamate decarboxylase genes in two families with pyridoxine-dependent epilepsy.</article-title>
                <source>J Hum Genet</source>
                <volume>43</volume>
                <fpage>128</fpage>
                <lpage>31</lpage>
                <pub-id pub-id-type="pmid">9621518</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.lee.1994.371">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kuhl</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gelbart</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kamimura</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>West</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beutler</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>1994</year>
                <article-title>Homology between a human protein and a protein of the green garden pea.</article-title>
                <source>Genomics</source>
                <volume>21</volume>
                <fpage>371</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">8088832</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.mahajnah.2016.60">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mahajnah</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corderio</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Austin</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Herd</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mutch</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carter</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Struys</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mercimek-Mahmutoglu</surname>
                    <given-names>S.</given-names>
                  </name>
                </person-group>
                <article-title>A prospective case study of the safety and efficacy of lysine-restricted diet and arginine supplementation therapy in a patient with pyridoxine-dependent epilepsy caused by mutations in ALDH7A1.</article-title>
                <source>Pediatr Neurol.</source>
                <year>2016</year>
                <volume>60</volume>
                <fpage>60</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">27212567</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.mercimekmahmutoglu.2014.741">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mercimek-Mahmutoglu</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cordeiro</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cruz</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hyland</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Struys</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kyriakopoulou</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mamak</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2014</year>
                <article-title>Novel therapy for pyridoxine dependent epilepsy due to ALDH7A1 genetic defect: L-arginine supplementation alternative to lysine-restricted diet.</article-title>
                <source>Eur J Paediatr Neurol.</source>
                <volume>18</volume>
                <fpage>741</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">25127453</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.marguet.2016.1435">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Marguet</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barakizou</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tebani</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abily-Donval</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Torre</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bayoudh</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jebnoun</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brasseur-Daudruy</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marret</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laquerriere</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bekri</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2016</year>
                <article-title>Pyridoxine-dependent epilepsy: report on three families with neuropathology.</article-title>
                <source>Metab Brain Dis.</source>
                <volume>31</volume>
                <fpage>1435</fpage>
                <lpage>43</lpage>
                <pub-id pub-id-type="pmid">27438048</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.mastrangelo.2012.24">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mastrangelo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leuzzi</surname>
                    <given-names>V</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Genes of early-onset epileptic encephalopathies: from genotype to phenotype.</article-title>
                <source>Pediatr Neurol</source>
                <volume>46</volume>
                <fpage>24</fpage>
                <lpage>31</lpage>
                <pub-id pub-id-type="pmid">22196487</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.mclachlan.1995.50">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>McLachlan</surname>
                    <given-names>RS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brown</surname>
                    <given-names>WF</given-names>
                  </name>
                </person-group>
                <year>1995</year>
                <article-title>Pyridoxine dependent epilepsy with iatrogenic sensory neuronopathy.</article-title>
                <source>Can J Neurol Sci</source>
                <volume>22</volume>
                <fpage>50</fpage>
                <lpage>1</lpage>
                <pub-id pub-id-type="pmid">7750075</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.mefford.2012.3190">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mefford</surname>
                    <given-names>HC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cook</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gospe</surname>
                    <given-names>SM</given-names>
                    <suffix>Jr</suffix>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Epilepsy due to 20q13.33 subtelomere deletion masquerading as pyridoxine-dependent epilepsy.</article-title>
                <source>Am J Med Genet A</source>
                <volume>158A</volume>
                <fpage>3190</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">23166088</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.mefford.2011.974">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mefford</surname>
                    <given-names>HC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yendle</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hsu</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cook</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Geraghty</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McMahon</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eeg-Olofsson</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sadleir</surname>
                    <given-names>LG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gill</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ben-Zeev</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lerman-Sagie</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mackay</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Freeman</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andermann</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pelakanos</surname>
                    <given-names>JT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andrews</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wallace</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eichler</surname>
                    <given-names>EE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berkovic</surname>
                    <given-names>SF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scheffer</surname>
                    <given-names>IE</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Rare copy number variants are an important cause of epileptic encephalopathies.</article-title>
                <source>Ann Neurol</source>
                <volume>70</volume>
                <fpage>974</fpage>
                <lpage>85</lpage>
                <pub-id pub-id-type="pmid">22190369</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.mefford.2015.756">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mefford</surname>
                    <given-names>HC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zemel</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Geraghty</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cook</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clayton</surname>
                    <given-names>PT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paul</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plecko</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mills</surname>
                    <given-names>PB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nordli</surname>
                    <given-names>DR</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Gospe</surname>
                    <given-names>SM</given-names>
                    <suffix>Jr</suffix>
                  </name>
                </person-group>
                <year>2015</year>
                <article-title>Intragenic deletions of ALDH7A1 in pyridoxine-dependent epilepsy caused by Alu-Alu recombination.</article-title>
                <source>Neurology</source>
                <volume>85</volume>
                <fpage>756</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">26224730</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.mikati.1991.215">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mikati</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trevathan</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krishnamoorthy</surname>
                    <given-names>KS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lombroso</surname>
                    <given-names>CT</given-names>
                  </name>
                </person-group>
                <year>1991</year>
                <article-title>Pyridoxine-dependent epilepsy: EEG investigations and long-term follow-up.</article-title>
                <source>Electroencephalogr Clin Neurophysiol</source>
                <volume>78</volume>
                <fpage>215</fpage>
                <lpage>21</lpage>
                <pub-id pub-id-type="pmid">1707793</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.mills.2014.1350">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mills</surname>
                    <given-names>PB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camuzeaux</surname>
                    <given-names>SS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Footitt</surname>
                    <given-names>EJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mills</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gissen</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fisher</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Das</surname>
                    <given-names>KB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Varadkar</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zuberi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McWilliam</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>St&#x000f6;dberg</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plecko</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baumgartner</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maier</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Calvert</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Riney</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wolf</surname>
                    <given-names>NI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Livingston</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bala</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morel</surname>
                    <given-names>CF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feillet</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raimondi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Del Giudice</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chong</surname>
                    <given-names>WK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pitt</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clayton</surname>
                    <given-names>PT</given-names>
                  </name>
                </person-group>
                <year>2014</year>
                <article-title>Epilepsy due to PNPO mutations: genotype, environment and treatment affect presentation and outcome.</article-title>
                <source>Brain</source>
                <volume>137</volume>
                <fpage>1350</fpage>
                <lpage>60</lpage>
                <pub-id pub-id-type="pmid">24645144</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.mills.2012.1031">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mills</surname>
                    <given-names>PB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Footitt</surname>
                    <given-names>EJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ceyhan</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waters</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clayton</surname>
                    <given-names>PT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Struys</surname>
                    <given-names>EA</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Urinary AASA excretion is elevated in patients with molybdenum cofactor deficiency and isolated sulphite oxidase deficiency.</article-title>
                <source>J Inherit Metab Dis.</source>
                <volume>35</volume>
                <fpage>1031</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">22403017</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.mills.2006.307">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mills</surname>
                    <given-names>PB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Struys</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plecko</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baxter</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baumgartner</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Willemsen</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Omran</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tacke</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uhlenberg</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weschke</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clayton</surname>
                    <given-names>PT</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Mutations in antiquitin in individuals with pyridoxine-dependent seizures.</article-title>
                <source>Nat Med</source>
                <volume>12</volume>
                <fpage>307</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">16491085</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.mills.2005.1077">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mills</surname>
                    <given-names>PB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Surtees</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Champion</surname>
                    <given-names>MP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beesley</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dalton</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scambler</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heales</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Briddon</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scheimberg</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoffmann</surname>
                    <given-names>GF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zschocke</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clayton</surname>
                    <given-names>PT</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Neonatal epileptic encephalopathy caused by mutations in the PNPO gene encoding pyridox(am)ine 5'-phosphate oxidase.</article-title>
                <source>Hum Mol Genet.</source>
                <volume>14</volume>
                <fpage>1077</fpage>
                <lpage>86</lpage>
                <pub-id pub-id-type="pmid">15772097</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.mills.2010.2148">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mills</surname>
                    <given-names>PB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Footitt</surname>
                    <given-names>EJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mills</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tuschl</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aylett</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Varadkar</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hemingway</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marlow</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rennie</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baxter</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dulac</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nabbout</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Craigen</surname>
                    <given-names>WJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schmitt</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feillet</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Christensen</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Lonlay</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pike</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hughes</surname>
                    <given-names>MI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Struys</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zuberi</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clayton</surname>
                    <given-names>PT</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Genotypic and phenotypic spectrum of pyridoxine-dependent epilepsy (ALDH7A1 deficiency).</article-title>
                <source>Brain.</source>
                <volume>133</volume>
                <fpage>2148</fpage>
                <lpage>59</lpage>
                <pub-id pub-id-type="pmid">20554659</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.nabbout.1999.f125">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nabbout</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Soufflet</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plouin</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dulac</surname>
                    <given-names>O</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Pyridoxine dependent epilepsy: a suggestive electroclinical pattern.</article-title>
                <source>Arch Dis Child Fetal Neonatal Ed.</source>
                <volume>81</volume>
                <fpage>F125</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">10448181</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.naasan.2009.293">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Naasan</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yabroudi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rahi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mikati</surname>
                    <given-names>MA</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Electroencephalographic changes in pyridoxine-dependant epilepsy: new observations.</article-title>
                <source>Epileptic Disord.</source>
                <volume>11</volume>
                <fpage>293</fpage>
                <lpage>300</lpage>
                <pub-id pub-id-type="pmid">20031502</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.nicolai.2006.164">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nicolai</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Kranen-Mastenbroek</surname>
                    <given-names>VH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wevers</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hurkx</surname>
                    <given-names>WA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vles</surname>
                    <given-names>JS</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Folinic acid-responsive seizures initially responsive to pyridoxine.</article-title>
                <source>Pediatr Neurol.</source>
                <volume>34</volume>
                <fpage>164</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">16458834</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.ohtsuka.1999.203">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ohtsuka</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hattori</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ishida</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ogino</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oka</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Long-term follow-up of an individual with vitamin B6-dependent seizures.</article-title>
                <source>Dev Med Child Neurol.</source>
                <volume>41</volume>
                <fpage>203</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">10210253</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.pearl.2013.139">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pearl</surname>
                    <given-names>PL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hyland</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chiles</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McGavin</surname>
                    <given-names>CL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yu</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taylor</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2013</year>
                <article-title>Partial Pyridoxine Responsiveness in PNPO Deficiency.</article-title>
                <source>JIMD Rep.</source>
                <volume>9</volume>
                <fpage>139</fpage>
                <lpage>42</lpage>
                <pub-id pub-id-type="pmid">23430561</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.p_rez.2013.239">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>P&#x000e9;rez</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guti&#x000e9;rrez-Solana</surname>
                    <given-names>LG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verd&#x000fa;</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Merinero</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yuste-Checa</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ruiz-Sala</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Calvo</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jalan</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mar&#x000ed;n</surname>
                    <given-names>LL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Campos</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ruiz</surname>
                    <given-names>M&#x000c1;</given-names>
                  </name>
                  <name name-style="western">
                    <surname>San Miguel</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>V&#x000e1;zquez</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Castro</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferrer</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Navarrete</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desviat</surname>
                    <given-names>LR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lapunzina</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ugarte</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>P&#x000e9;rez-Cerd&#x000e1;</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2013</year>
                <article-title>Clinical, biochemical, and molecular studies in pyridoxine-dependent epilepsy. Antisense therapy as possible new therapeutic option.</article-title>
                <source>Epilepsia.</source>
                <volume>54</volume>
                <fpage>239</fpage>
                <lpage>48</lpage>
                <pub-id pub-id-type="pmid">23350806</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.plecko.2005.200">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Plecko</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hikel</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Korenke</surname>
                    <given-names>GC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schmitt</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baumgartner</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baumeister</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Struys</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Erwa</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stockler-Ipsiroglu</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Pipecolic acid as a diagnostic marker of pyridoxine-dependent epilepsy.</article-title>
                <source>Neuropediatrics</source>
                <volume>36</volume>
                <fpage>200</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">15944906</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.plecko.2014.1425">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Plecko</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paul</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mills</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clayton</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paschke</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maier</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hasselmann</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schmiedel</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kanz</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Connolly</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wolf</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Struys</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stockler</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abela</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hover</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2014</year>
                <article-title>Pyridoxine responsiveness in novel mutations of the PNPO gene.</article-title>
                <source>Neurology.</source>
                <volume>82</volume>
                <fpage>1425</fpage>
                <lpage>33</lpage>
                <pub-id pub-id-type="pmid">24658933</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.plecko.2007.19">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Plecko</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paul</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paschke</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stoeckler-Ipsiroglu</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Struys</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hartmann</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Luecke</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>di Capua</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Korenke</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hikel</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reutershahn</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Freilinger</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baumeister</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bosch</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Erwa</surname>
                    <given-names>W</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Biochemical and molecular characterization of 18 patients with pyridoxine-dependent epilepsy and mutations of the antiquitin (ALDH7A1) gene.</article-title>
                <source>Hum Mutat.</source>
                <volume>28</volume>
                <fpage>19</fpage>
                <lpage>26</lpage>
                <pub-id pub-id-type="pmid">17068770</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.poliachik.2016.43">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Poliachik</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Friedman</surname>
                    <given-names>SD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poliakov</surname>
                    <given-names>AV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Budech</surname>
                    <given-names>CB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ishak</surname>
                    <given-names>GE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shaw</surname>
                    <given-names>DW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gospe</surname>
                    <given-names>SM</given-names>
                    <suffix>Jr</suffix>
                  </name>
                </person-group>
                <year>2016</year>
                <article-title>Corpus callosum diffusion and connectivity features in high functioning subjects with pyridoxine-dependent epilepsy.</article-title>
                <source>Pediatr Neurol.</source>
                <volume>54</volume>
                <fpage>43</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">26547255</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.rankin.2007.300">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rankin</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harrison</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chong</surname>
                    <given-names>WK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boyd</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aylett</surname>
                    <given-names>SE</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Pyridoxine-dependent seizures: a family phenotype that leads to severe cognitive deficits, regardless of treatment regime.</article-title>
                <source>Dev Med Child Neurol</source>
                <volume>49</volume>
                <fpage>300</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">17376142</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.reid.2016.79">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Reid</surname>
                    <given-names>ES</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Williams</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stabej Ple</surname>
                    <given-names>Q</given-names>
                  </name>
                  <name name-style="western">
                    <surname>James</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ocaka</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bacchelli</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Footitt</surname>
                    <given-names>EJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boyd</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cleary</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mills</surname>
                    <given-names>PB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clayton</surname>
                    <given-names>PT</given-names>
                  </name>
                </person-group>
                <year>2016</year>
                <article-title>Seizures due to a KCNQ2 mutation: treatment with vitamin B6.</article-title>
                <source>JIMD Rep.</source>
                <volume>27</volume>
                <fpage>79</fpage>
                <lpage>84</lpage>
                <pub-id pub-id-type="pmid">26446091</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.salomons.2007.414">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bok</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Struys</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pope</surname>
                    <given-names>LL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Darmin</surname>
                    <given-names>PS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mills</surname>
                    <given-names>PB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clayton</surname>
                    <given-names>PT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Willemsen</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>An intriguing "silent" mutation and a founder effect in antiquitin (ALDH7A1).</article-title>
                <source>Ann Neurol.</source>
                <volume>62</volume>
                <fpage>414</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">17721876</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.scharer.2010.571">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Scharer</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brocker</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vasiliou</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Creadon-Swindell</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gallagher</surname>
                    <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spector</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Hove</surname>
                    <given-names>JL</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>The genotypic and phenotypic spectrum of pyridoxine-dependent epilepsy due to mutations in ALDH7A1.</article-title>
                <source>J Inherit Metab Dis.</source>
                <volume>33</volume>
                <fpage>571</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">20814824</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.schmitt.2010.e133">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schmitt</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baumgartner</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mills</surname>
                    <given-names>PB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clayton</surname>
                    <given-names>PT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keller</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wohlrab</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Seizures and paroxysmal events: symptoms pointing to the diagnosis of pyridoxine-dependent epilepsy and pyridoxine phosphate oxidase deficiency.</article-title>
                <source>Dev Med Child Neurol.</source>
                <volume>52</volume>
                <fpage>e133</fpage>
                <lpage>42</lpage>
                <pub-id pub-id-type="pmid">20370816</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.stockler.2011.48">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Stockler</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plecko</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gospe</surname>
                    <given-names>SM</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Coulter-Mackie</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Connolly</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Karnebeek</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mercimek-Mahmutoglu</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hartmann</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scharer</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Struijs</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tein</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clayton</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Hove</surname>
                    <given-names>JL</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Pyridoxine dependent epilepsy and antiquitin deficiency: clinical and molecular characteristics and recommendations for diagnosis, treatment and follow-up.</article-title>
                <source>Mol Genet Metab.</source>
                <volume>104</volume>
                <fpage>48</fpage>
                <lpage>60</lpage>
                <pub-id pub-id-type="pmid">21704546</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.striano.2009.933">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Striano</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Battaglia</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giordano</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Capovilla</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beccaria</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Struys</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Two novel ALDH7A1 (antiquitin) splicing mutations associated with pyridoxine-dependent seizures.</article-title>
                <source>Epilepsia.</source>
                <volume>50</volume>
                <fpage>933</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">18717709</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.struys.2012.e1716">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Struys</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nota</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bakkali</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al Shahwan</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tabarki</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <article-title>Pyridoxine-dependent epilepsy with elevated urinary &#x003b1;-amino adipic semialdehyde in molybdenum cofactor deficiency.</article-title>
                <source>Pediatrics.</source>
                <year>2012</year>
                <volume>130</volume>
                <fpage>e1716</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">23147983</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.tlili.2013.242">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tlili</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hamida Hentati</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chaabane</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gargouri</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fakhfakh</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2013</year>
                <article-title>Pyridoxine-dependent epilepsy in Tunisia is caused by a founder missense mutation of the ALDH7A1 gene.</article-title>
                <source>Gene.</source>
                <volume>518</volume>
                <fpage>242</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">23376216</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.torres.1999.529">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Torres</surname>
                    <given-names>OA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miller</surname>
                    <given-names>VS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buist</surname>
                    <given-names>NM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hyland</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Folinic acid-responsive neonatal seizures.</article-title>
                <source>J Child Neurol.</source>
                <volume>14</volume>
                <fpage>529</fpage>
                <lpage>32</lpage>
                <pub-id pub-id-type="pmid">10456764</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.van_karnebeek.2014.1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van Karnebeek</surname>
                    <given-names>CD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stockler-Ipsiroglu</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jaggumantri</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Assmann</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baxter</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buhas</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bok</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cheng</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coughlin</surname>
                    <given-names>CR</given-names>
                    <suffix>2nd</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Das</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giezen</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al-Hertani</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ho</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meyer</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mills</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plecko</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Struys</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ueda</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Albersen</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verhoeven</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gospe</surname>
                    <given-names>SM</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Gallagher</surname>
                    <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Hove</surname>
                    <given-names>JK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hartmann</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2014</year>
                <article-title>Lysine-restricted diet as adjunct therapy for pyridoxine-dependent epilepsy: The PDE Consortium Consensus Recommendations.</article-title>
                <source>JIMD Rep.</source>
                <volume>15</volume>
                <fpage>1</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">24748525</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.van_karnebeek.2015">
              <mixed-citation publication-type="book">van Karnebeek CD, Gospe SM Jr. Disorders of pyridoxine metabolism. In: Rosenberg E, Pascual J, eds. <italic toggle="yes">Rosenberg&#x02019;s Molecular and Genetic Basis of Neurological and Psychiatric Disease.</italic> 5 ed. Philadelphia, PA: Elsevier. 2015.</mixed-citation>
            </ref>
            <ref id="pds.REF.van_karnebeek.2012.335">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van Karnebeek</surname>
                    <given-names>CD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hartmann</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jaggumantri</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bok</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cheng</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Connolly</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coughlin</surname>
                    <given-names>CR</given-names>
                    <suffix>2nd</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Das</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gospe</surname>
                    <given-names>SM</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Lee</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mercimek-Mahmutoglu</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meyer</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Struys</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sinclair</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Hove</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collet</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plecko</surname>
                    <given-names>BR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stockler</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Lysine restricted diet for pyridoxine-dependent epilepsy: first evidence and future trials.</article-title>
                <source>Mol Genet Metab.</source>
                <volume>107</volume>
                <fpage>335</fpage>
                <lpage>44</lpage>
                <pub-id pub-id-type="pmid">23022070</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.van_karnebeek.2016.6">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van Karnebeek</surname>
                    <given-names>CD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tiebout</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niermeijer</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poll-The</surname>
                    <given-names>BT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ghani</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coughlin</surname>
                    <given-names>CR</given-names>
                    <suffix>2nd</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Van Hove</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richter</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Christen</surname>
                    <given-names>HJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gallagher</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hartmann</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stockler-Ipsiroglu</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2016</year>
                <article-title>Pyridoxine-dependent epilepsy: an expanding clinical spectrum.</article-title>
                <source>Pediatr Neurol.</source>
                <volume>59</volume>
                <fpage>6</fpage>
                <lpage>12</lpage>
                <pub-id pub-id-type="pmid">26995068</pub-id>
              </element-citation>
            </ref>
            <ref id="pds.REF.wang.2005.512">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>HS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chou</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hung</surname>
                    <given-names>PC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lin</surname>
                    <given-names>KL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hsieh</surname>
                    <given-names>MY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chang</surname>
                    <given-names>MY</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Pyridoxal phosphate is better than pyridoxine for controlling idiopathic intractable epilepsy.</article-title>
                <source>Arch Dis Child</source>
                <volume>90</volume>
                <fpage>512</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">15851435</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="pds.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="pds.Author_Notes">
          <title>Author Notes</title>
          <p>
            <bold>Pyridoxine-Dependent Epilepsy Patient Registry</bold>
          </p>
          <p>For diagnosed patients, operated by the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.pdeonline.org">PDE Consortium</ext-link>. The registry may be contacted through the author or at pde@cw.bc.ca.</p>
        </sec>
        <sec id="pds.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>13 April 2017 (ma) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>19 June 2014 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>7 June 2012 (sg) Revision: <xref ref-type="table" rid="pds.T.molecular_genetic_testing_used_in">Table 1</xref> updated</p>
            </list-item>
            <list-item>
              <p>26 April 2012 (sg) Revision: additions to molecular genetic testing table (<xref ref-type="table" rid="pds.T.molecular_genetic_testing_used_in">Table 1</xref>); references added</p>
            </list-item>
            <list-item>
              <p>1 March 2012 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>10 November 2009 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>24 July 2007 (cd) Revision: clinical testing available: analyte and sequence analysis; prenatal diagnosis</p>
            </list-item>
            <list-item>
              <p>9 June 2006 (sg) Revision: mutations in <italic toggle="yes">ALDH7A1</italic> found to be causative</p>
            </list-item>
            <list-item>
              <p>8 March 2006 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>18 December 2003 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>7 December 2001 (me) Review posted to the live Web site</p>
            </list-item>
            <list-item>
              <p>17 September 2001 (sg) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
